Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 6Active not recruiting 3Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 11Nivolumab 6fludarabine phosphate 5fludarabine 5Paclitaxel 5Cisplatin 5Cetuximab 5Carboplatin 5atezolizumab 4Pemetrexed 4Docetaxel 4Cyclophosphamide 4Bevacizumab 4durvalumab 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Ipilimumab 3venetoclax 2ibrutinib 2enzalutamide 2encorafenib 2binimetinib 2Trastuzumab 2Taxes 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Practice Guidelines as Topic 2Platinum 2Oxaliplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × ivosidenib × 30 days × Clear all
NCT04250051 2026-06-01

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Northwestern University

Phase 1 Terminated
2 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡